<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12553886
    </Internal_Number>
    <TrialID>NCT05471544
    </TrialID>
    <Last_Refreshed_on>3 October 2022
    </Last_Refreshed_on>
    <Public_title>Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan
    </Public_title>
    <Scientific_title>Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in Northern Bahr Eel Ghazal, South Sudan: A Type 2 Hybrid Effectiveness-implementation Study Using a Convergent Mixed-methods Approach
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Malaria Consortium
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220715
    </Date_registration3>
    <Date_registration>15/07/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05471544
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3 Months
    </Inclusion_agemin>
    <Inclusion_agemax>59 Months
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 18, 2022
    </Date_enrollement>
    <Target_size>3575
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>South Sudan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ahmed Ismail Julla
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ministry of Health South Sudan
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Being resident in the project area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Afebrile with no other malaria associated symptoms in the past 48 hours or at time of&#x0D;&lt;br&gt;             recruitment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Consent to participate in the study obtained&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Can comply with 3 day DOT of standard SPAQ regimen (day 0-2)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness and ability of the childs guardians to comply with the study protocol for&#x0D;&lt;br&gt;             the duration of the study including all dry blood spot and slide collections&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Symptoms of malaria (tympanic fever = 37.5 °C or history of fever in past 48 hours)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known allergy to medicine provided&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receiving a sulfa-based medication for treatment or prophylaxis, including&#x0D;&lt;br&gt;             co-trimoxazole (trimethoprim-sulfamethoxazole).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals receiving azithromycin due to the antimalarial activity of azithromycin.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe malnutrition according to WHO guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Recruited in cross sectional surveys or any other SMC studies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children with HIV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous treatment with Amodiaquine in the past 28 days (treatment with ASAQ or SPAQ)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Malaria
    </Condition>
    <Intervention>Drug: Sulfadoxine pyrimethamine;Drug: Amodiaquine
    </Intervention>
    <Primary_outcome>Malaria incidence in study population in intervention county and eligible children in one control county;Chemoprevention failure as defined by positive parasites in malaria slides after day 7 or positive qPCR in dried blood spot (DBS) on day 28;Prevalence of antimalarial resistance markers (dhfr, dhps, Pfcrt, pfmdr1) among chemoprevention failures as defined in outcome 2;Drug concentrations of Sulfadoxine-pyrimethamine and amodiaquine among chemoprevention failures (as defined in outcome 1)
    </Primary_outcome>
    <Secondary_ID>SMCSSPHASE1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12439265
    </Internal_Number>
    <TrialID>NCT05449717
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
    </Public_title>
    <Scientific_title>A Prospective Cohort Study on the Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis After Treatment for Primary Visceral Leishmaniasis in South Sudan
    </Scientific_title>
    <Acronym>PKDL
    </Acronym>
    <Primary_sponsor>Epicentre
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220704
    </Date_registration3>
    <Date_registration>04/07/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05449717
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 31, 2022
    </Date_enrollement>
    <Target_size>367
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>South Sudan;South Sudan;South Sudan;South Sudan
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Rebecca M Coulborn, MPH;Margriet den Boer, MD;Rebecca M Coulborn, MPH;Margriet den Boer, MD;Rebecca M Coulborn, MPH;Margriet den Boer, MD;Rebecca M Coulborn, MPH;Margriet den Boer, MD;Rebecca M Coulborn, MPH;Margriet den Boer, MD;Rebecca M Coulborn, MPH;Margriet den Boer, MD;Rebecca M Coulborn, MPH;Margriet den Boer, MD;Rebecca M Coulborn, MPH;Margriet den Boer, MD
    </Contact_Lastname>
    <Contact_Email>;;rebecca.coulborn@epicentre.msf.org;Margriet.den.boer@london.msf.org;;;rebecca.coulborn@epicentre.msf.org;Margriet.den.boer@london.msf.org;;;rebecca.coulborn@epicentre.msf.org;Margriet.den.boer@london.msf.org;;;rebecca.coulborn@epicentre.msf.org;Margriet.den.boer@london.msf.org
    </Contact_Email>
    <Contact_Tel>;;+33 1 40 21 55 55;+44 20 7404 6600;;;+33 1 40 21 55 55;+44 20 7404 6600;;;+33 1 40 21 55 55;+44 20 7404 6600;;;+33 1 40 21 55 55;+44 20 7404 6600
    </Contact_Tel>
    <Contact_Affiliation>Epicentre;Medecins Sans Frontieres, Netherlands;;Epicentre;Medecins Sans Frontieres, Netherlands;;Epicentre;Medecins Sans Frontieres, Netherlands;;Epicentre;Medecins Sans Frontieres, Netherlands;
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12515771
    </Internal_Number>
    <TrialID>NCT05364593
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Evaluation of Point-of-care Ultrasound in Children From 6 Months to 15 Years With Presumptive Tuberculosis
    </Public_title>
    <Scientific_title>Evaluating Point-of-care Ultrasound to Improve Tuberculosis Diagnosis in Children
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medecins Sans Frontieres, Spain
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220426
    </Date_registration3>
    <Date_registration>26/04/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05364593
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Months
    </Inclusion_agemin>
    <Inclusion_agemax>15 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 26, 2019
    </Date_enrollement>
    <Target_size>320
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Guinea-Bissau;South Sudan;Guinea-Bissau;South Sudan
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Laura Moretó, MD, MIH;Sabine Belard, MD, PhD;Laura Moretó Planas, MD, MIH;Lazro Fidelle, MD
    </Contact_Lastname>
    <Contact_Email>;;laura.moreto@barcelona.msf.org;msfe-malakal-research@barcelona.msf.org
    </Contact_Email>
    <Contact_Tel>;;+34636440034;+249927729005
    </Contact_Tel>
    <Contact_Affiliation>MSF OCBA;University Hospital Tuebingen;
    </Contact_Affiliation>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12517828
    </Internal_Number>
    <TrialID>ISRCTN45167024
    </TrialID>
    <Last_Refreshed_on>5 September 2022
    </Last_Refreshed_on>
    <Public_title>Eczema monitoring online via questionnaires
    </Public_title>
    <Scientific_title>Evaluation of the effect of symptom monitoring with patient-reported outcome measures on clinical outcomes in eczema: an online, parallel-group randomised controlled trial (EMO trial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University of Nottingham
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210629
    </Date_registration3>
    <Date_registration>29/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN45167024
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>14/09/2021
    </Date_enrollement>
    <Target_size>266
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Online parallel-group randomized controlled clinical trial (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Self-report or parent/carer report of eczema diagnosis by a healthcare professional&lt;br&gt;                2. Person aged 1 year or older&lt;br&gt;                3. Able and willing to provide informed consent&lt;br&gt;                4. If under 16 years old, a parent/carer needs to provide informed consent on behalf of the child&lt;br&gt;                5. Able to read and understand written English&lt;br&gt;                6. Have access to the internet and to an internet-enabled device&lt;br&gt;                7. POEM score of 3 or above at eligibility screening&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Unable/unwilling to provide informed consent&lt;br&gt;                2. Currently taking part in another eczema clinical trial&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Eczema &lt;br&gt;Skin and Connective Tissue Diseases &lt;br&gt;Dermatitis and eczema
    </Condition>
    <Intervention>This is a methodological trial and there will be no treatment intervention involved. The intervention will be the online Patient Oriented Eczema Measure (POEM) questionnaire. Eligible participants will be randomised online and assigned to either the intervention group or to the control group using the REDCap software. The randomisation schedule will be based on computer-generated codes using random permuted blocks of varying size, stratified by age and baseline disease severity. The PhD student will deal with participant queries, thus she will have access to group allocation, but the other trial team members and the trial statistician will remain blinded. Participants in the intervention group (weekly group) will be asked to complete the POEM questionnaire weekly for 8 weeks. The control group will not receive the intervention.
    </Intervention>
    <Primary_outcome>Eczema severity measured by the self-reported or proxy (parent/carer reported) POEM questionnaire score at baseline and 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Adherence to eczema treatment use, assessed in two ways:&lt;br&gt;                1.1. Eczema treatment use assessed by the emollient and topical corticosteroid use questionnaire over the last week from baseline to 8 weeks&lt;br&gt;                1.2. Eczema treatment use assessed by the overall eczema treatment use questionnaire 2 months prior to joining the study and at the end of the study at 8 weeks&lt;br&gt;                2. Missing data: the proportion of fully completed questionnaires at 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;EMO 120421
    </Secondary_ID>
    <Source_Support>University of Nottingham
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 23/04/2021, Faculty of Medicine &amp; Health Science Research Ethics Committee, University of Nottingham (Faculty Hub, Room E41, E Floor, Medical School, Queen's Medical Centre Campus, Nottingham University Hospitals, Nottingham, NG7 2UH, UK; +44 (0) 115 74 85060; FMHS-ResearchEthics@nottingham.ac.uk), ref: 239-0421
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>03/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12373275
    </Internal_Number>
    <TrialID>ISRCTN12329547
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital depression management application: juli
    </Public_title>
    <Scientific_title>Randomised control trial of a digital depression management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN12329547
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>476
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    Juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Depression with PHQ-8 score &gt;4 at baseline&lt;br&gt;                2. Age 18 to 65 years (inclusive)&lt;br&gt;                3. English speakers&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. PHQ-8 &lt;5 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Depression &lt;br&gt;Mental and Behavioural Disorders &lt;br&gt;Depressive episode, unspecified
    </Condition>
    <Intervention>&lt;br&gt;                Participants will be randomly allocated using an online tool to receive the juli app or treatment as usual plus an attention placebo control app.&lt;br&gt;&lt;br&gt;                The participant will use the juli app for 8 weeks and complete a depression symptoms questionnaire every 2 weeks (four in total). Participants will also be asked to complete a wellbeing questionnaire at 4 and 8 weeks and a user satisfaction questionnaire at 8 weeks. These are all standardised questionnaires, commonly used for research (the 8-item Patient Health Questionnaire, the 12-item Short Form survey of health-related quality of life and the Mobile Health App Usability Questionnaire).&lt;br&gt;&lt;br&gt;                The full version of the app presents the participant with graphical displays of some data automatically generated from their phone and smartwatch. The types of data are:&lt;br&gt;                1. Sleep – time in bed and time asleep&lt;br&gt;                2. Activity – steps and flights of stairs climbed&lt;br&gt;                3. Heart rate variability – the variation in the time interval between heartbeats&lt;br&gt;                4. Workouts – periods of exercise&lt;br&gt;                5. Oxygen saturation&lt;br&gt;                6. Menstrual cycle&lt;br&gt;&lt;br&gt;                It also presents them with external data: weather, pollen count and air quality (provided via geolocation). It asks the participant to rate how they are feeling and answer questions about their mood on a daily basis. It allows them to set a medication reminder, and add notes to a journal. It presents them with correlations between these different types of data and helps them to identify things that make their mood better or worse.&lt;br&gt;&lt;br&gt;                Participants allocated to the dummy version of the app will be asked to rate how they are feeling on a daily basis, but will not
    </Intervention>
    <Primary_outcome>Depression symptoms measured using the eight-item Patient Health Questionnaire (PHQ-8) at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Depression symptoms measured using the PHQ-8 at 2, 4 and 6 weeks&lt;br&gt;                2. Health-related quality of life measured using Short Form 12 (SF-12) Item at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known
    </Secondary_ID>
    <Source_Support>Juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics Committee (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12373274
    </Internal_Number>
    <TrialID>ISRCTN87679686
    </TrialID>
    <Last_Refreshed_on>27 June 2022
    </Last_Refreshed_on>
    <Public_title>Trial of a digital asthma management application: juli
    </Public_title>
    <Scientific_title>Randomised controlled trial of a digital asthma management application: juli                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210608
    </Date_registration3>
    <Date_registration>08/06/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN87679686
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>180
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional placebo-controlled randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Bettina
    </Contact_Firstname>
    <Contact_Lastname>Dührkoop
    </Contact_Lastname>
    <Contact_Address>
                    juli Health
                    23 Beach Ave
                
    </Contact_Address>
    <Contact_Email>bd@juli.co
    </Contact_Email>
    <Contact_Tel>+44 (0)20 7679 9736
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Asthma with Asthma Control Test score&lt;20 at baseline&lt;br&gt;                2. Age 18 to 65 (inclusive)&lt;br&gt;                3. English speaker&lt;br&gt;                4. Have an iPhone&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Asthma Control Test&gt;19 at baseline&lt;br&gt;                2. Children&lt;br&gt;                3. Non-English speakers&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Reduction of asthma symptoms in adults with asthma &lt;br&gt;Respiratory &lt;br&gt;Asthma
    </Condition>
    <Intervention>&lt;br&gt;                Use of juli app vs treatment as usual (plus attention placebo control app).&lt;br&gt;&lt;br&gt;                juli app: Participants will be prompted to open the app each day via an automated alert. They will be asked to rate how they are feeling on a scale using 5 emojis and track number of shortness of breath episodes, rescue inhaler usage and night time waking with shortness of breath. The app will gather information via Apple HealthKit; sleep, activity, workouts, oxygen saturation. It will present this data to the participant and show associations with asthma symptoms. It will make recommendations about these parameters to guide healthy behaviours and will use external data sources (weather, air quality, pollen count) to guide these recommendations. The app has a medication reminder function that can be set by the participants to improve medication adherence. Participants are also encouraged to engage in journaling via the app, especially in relation to exacerbating or reliving factors for asthma symptoms.&lt;br&gt;&lt;br&gt;                Attention placebo control app: Participants will be prompted to open the app each day via an automated alert and rate how they are feeling on a scale using 5 emojis.&lt;br&gt;&lt;br&gt;                The participant will use the app for eight weeks and complete an asthma questionnaire every two weeks (four in total). Participants will also be asked to complete a well-being questionnaire at four and eight weeks and a user satisfaction questionnaire at eight weeks.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Asthma symptoms measured using the Asthma Control Test at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Asthma symptoms measured using the Asthma Control Test at 2, 4, and 6 weeks&lt;br&gt;                2. Short Form 12 Item health-related quality of life at 4 and 8 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;Nil known
    </Secondary_ID>
    <Source_Support>juli Health
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 07/06/2021, UCL Research Ethics (Office of the Vice-Provost (Research), University College London, 2 Taviton St, London, WC1E 6BT, UK; +44 (0)20 7679 8717; ethics@ucl.ac.uk), ref: 19413/001
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/08/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>10750449
    </Internal_Number>
    <TrialID>ISRCTN56646695
    </TrialID>
    <Last_Refreshed_on>22 March 2021
    </Last_Refreshed_on>
    <Public_title>Integrating self-affirmation content into a smoking cessation mobile app
    </Public_title>
    <Scientific_title>Integrating the use of self-affirmation content into a mobile app to promote quit attempts with text-based smoking cessation intervention messaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>National Cancer Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210212
    </Date_registration3>
    <Date_registration>12/02/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN56646695
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>07/03/2018
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized 2 x 2 factorial design (integrated affirmation: affirmation texts present versus absent; baseline affirmation: questionnaire present versus absent) (Prevention)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Elizabeth
    </Contact_Firstname>
    <Contact_Lastname>Seaman
    </Contact_Lastname>
    <Contact_Address>600 Peachtree St NE #1000
    </Contact_Address>
    <Contact_Email>eseaman@cdcfoundation.org
    </Contact_Email>
    <Contact_Tel>+1 (0)4438524139
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                A randomly selected proportion of users who downloaded the free version of the Smoke Free-Quit Smoking Now mobile application during the study period (initially 10% and then increased to 30% to achieve recruitment goals) are shown a consent form and invited to participate in this study. Once participants who opted in completed the baseline assessment, their eligibility was determined. In order to participate, app users had to be:&lt;br&gt;                1. Adults (between the ages of 18-98)&lt;br&gt;                2. Selected a cessation date after the day they downloaded the app but not more than 14 days in the future&lt;br&gt;                3. Completed the baseline assessment&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Under 18 years or over 98 years old&lt;br&gt;                2. Selected a quit date more than 14 days in the future or more than 1 day in the past&lt;br&gt;                3. Paid for additional app features (Pro users)&lt;br&gt;                4. Did not complete the baseline assessment&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Smoking cessation among current smokers &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>Two types of self-affirmation inductions (Integrated, Baseline) were added to a publicly available smoking cessation mobile application (Smoke-Free Quit Smoking Now). All users who met the inclusion criteria, provided consent to participate and completed a baseline assessment, were randomized to 1 of 4 conditions. Half of the participants were randomly assigned to complete a self-affirmation induction upon study entry. Orthogonally, half of the participants were randomly assigned to receive self-affirming text notifications during their quit attempt or to receive conventional notifications. The induction and the text notifications were fully automated, and all data were collected through self-assessments in the mobile application. Self-reported smoking cessation was assessed 1 month and 3 months following study entry.
    </Intervention>
    <Primary_outcome>Smoking cessation measured through self-assessments in the mobile application: past-week cessation at 1 month, past-month cessation at 1 month, past-week cessation at 3 months, and past-month cessation at 3 months
    </Primary_outcome>
    <Secondary_outcome>Optimism and baseline mood states (happiness, anger, anxiousness, hopefulness, sadness) measured through self-assessments in the mobile application at baseline 
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;17CN039
    </Secondary_ID>
    <Source_Support>National Cancer Institute
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 12/04/2018, the National Institutes of Health Intramural Institutional Review Board (Office of Human Subjects Research Protections, 6700B Rockledge Drive, Suite 4300, Bethesda, MD 20817, USA; +1 301 402 3713; irb@od.nih.gov), ref: #17CN039
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>06/03/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>10420986
    </Internal_Number>
    <TrialID>ISRCTN95140761
    </TrialID>
    <Last_Refreshed_on>5 January 2021
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following surgery of the pancreas
    </Public_title>
    <Scientific_title>International Pancreatic Surgery Outcomes Study - PancreasGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201203
    </Date_registration3>
    <Date_registration>03/12/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN95140761
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2021
    </Date_enrollement>
    <Target_size>3500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cohort study (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Adults 18 years of age or older&lt;br&gt;                2. All indications (including benign and malignant)&lt;br&gt;                3. Open, laparoscopic or robotic&lt;br&gt;                4. Elective or emergency&lt;br&gt;                5. Partial or total pancreatectomies&lt;br&gt;                6. Pancreatic tumour enucleations&lt;br&gt;                7. Procedures with concomitant vascular or other organ resections&lt;br&gt;                8. Pancreatic duct drainage procedures (e.g. Frey, Puestow, or Beger)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Pancreas or islet cell transplantation&lt;br&gt;                2. Transcutaneous or transgastric imaging-guided ablation (e.g. RFA) or electroporation (e.g. NanoKnife)&lt;br&gt;                3. Endoscopic (e.g. ERCP, stent or lithotripsy) procedures&lt;br&gt;                4. Endoscopic transgastric and surgical necrosectomies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Patients with pancreatic disease requiring surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>Participants, agreeing to be part of this study, will be observed from the date of surgery until hospital discharge as well as 90 days after their operation. Fully anonymised data will be collected including the participant, their disease, operation characteristics as well as outcomes, such as events including death and illness.
    </Intervention>
    <Primary_outcome>Mortality rate 90 days postoperatively measured using patient records
    </Primary_outcome>
    <Secondary_outcome>Morbidity as defined by the Clavien-Dindo Classification and measured by the Comprehensive Complications Index ® (CCI®) at 90 days postoperatively measured using patient records
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;RFH287_20-21
    </Secondary_ID>
    <Source_Support>Royal Free Charity - Fiorina Fund
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>No ethics approval required. Registered and approved as an audit by the Royal Free Hospital Quality Governance Department with the ID number RFH287_20-21
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/03/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12635176
    </Internal_Number>
    <TrialID>ISRCTN13539303
    </TrialID>
    <Last_Refreshed_on>31 October 2022
    </Last_Refreshed_on>
    <Public_title>An international registry of coronavirus exposure in pregnancy
    </Public_title>
    <Scientific_title>International Registry of Coronavirus Exposure in Pregnancy (IRCEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Pregistry LLC
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>30/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN13539303
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Female
    </Inclusion_gender>
    <Date_enrollement>08/06/2020
    </Date_enrollement>
    <Target_size>25000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Prospective observational study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan
    </Countries>
    <Contact_Firstname>Diego;Sonia
    </Contact_Firstname>
    <Contact_Lastname>Wyszynski;Hernandez-Diaz
    </Contact_Lastname>
    <Contact_Address>
                    1801 Century Park East
                    25th Floor
                ;677 Huntington Avenue
    </Contact_Address>
    <Contact_Email>hello@pregistry.com;shernan@hsph.harvard.edu
    </Contact_Email>
    <Contact_Tel>+1 (747) 200-5468;+1 (617) 432-3942
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Adult pregnant women with clinical confirmation of COVID-19 or tested for SARS-CoV-2 at any time during their pregnancy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Subjects who do not meet the inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) during pregnancy &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The IRCEP will be an observational cohort study with prospective and retrospective components. Registration and participation via website or mobile app specially developed for the IRCEP will be voluntary. Women 18 years of age and older will be encouraged to enrol if at any time during pregnancy, they had a test performed for the coronavirus (regardless of the result) or if they had clinical confirmation of COVID-19 in the absence of a SARS-CoV-2 test. Women with confirmed COVID-19 via clinical or test methods will be included in the exposed group and women with a negative test will be included in the control group. Eligible women will be able to enrol at any time during gestation. Given the public health emergency due to the COVID-19 pandemic and the urgent need for data, the IRCEP will also enrol eligible women retrospectively during the first 180 days after delivery (if they delivered after December 2019).&lt;br&gt;&lt;br&gt;                As numbers accumulate, the natural history of COVID-19 during pregnancy will be reported stratified by days since COVID-19 confirmation at enrollment (i.e., from prospective if immediate to retrospective if enrolled after resolution) and the risk of pregnancy outcomes by COVID-19 exposure group will be reported stratified by trimester at enrollment. For the assessment of miscarriages, only participants enrolled during the first trimester will be included and the analyses will be stratified by gestational week at enrollment. For other outcomes, the primary analysis will include all enrollees. However, sensitivity analyses of 1) teratogenicity will be restricted to participants enrolled before an informative prenatal screening was done; 2) late-pregnancy outcomes (e.g. preeclampsia) will be restricted to participants enrolled before 
    </Intervention>
    <Primary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire at baseline:&lt;br&gt;                1. Pregnancy outcomes:&lt;br&gt;                1.1. Miscarriage (or spontaneous abortion)&lt;br&gt;                1.2. Elective termination&lt;br&gt;                1.3. Stillbirth&lt;br&gt;                1.4. Preterm delivery&lt;br&gt;                2. Birth outcomes (measured at additional time points up to 90 days):&lt;br&gt;                2.1. Major structural defects&lt;br&gt;                2.2. Neonatal death&lt;br&gt;                2.3. Admission into the Neonatal Intensive Care Unit&lt;br&gt;                2.4. Maternal obstetric complications&lt;br&gt;                2.5. Post-partum health&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Measured by maternal self-report using online questionnaire:&lt;br&gt;                1. Head circumference (cm) at each time point from baseline to 90 days.&lt;br&gt;                2. Length at birth (cm)&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT04366986;Nil known
    </Secondary_ID>
    <Source_Support>Pregistry LLC
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 08/06/2020, Institutional Review Board (IRB) of the Harvard T.H. Chan School of Public Health (90 Smith Street, 3rd Floor Boston, MA 02120, USA; +1 (617) 432-5132; kninsala@hsph.harvard.edu), ref: # IRB20-0622
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/04/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12530559
    </Internal_Number>
    <TrialID>ISRCTN85785540
    </TrialID>
    <Last_Refreshed_on>12 September 2022
    </Last_Refreshed_on>
    <Public_title>Evaluating an app to help people quit smoking
    </Public_title>
    <Scientific_title>Effectiveness of an offer of the Smoke Free smartphone application for smoking cessation compared with no support: the App for Smoking ceSsation Evaluation Trial (ASSET)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>University College London
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201015
    </Date_registration3>
    <Date_registration>15/10/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN85785540
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/08/2020
    </Date_enrollement>
    <Target_size>3116
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Interventional randomized controlled trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe;Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Aged at least 18 years&lt;br&gt;                2. Able to provide consent&lt;br&gt;                3. English speaker&lt;br&gt;                4. Owns a smartphone&lt;br&gt;                5. Current cigarette smoker&lt;br&gt;                6. Willing to be followed-up by e-mail and complete online questionnaires after 1, 4 and 30 weeks&lt;br&gt;                7. Interested in making a quit attempt within the next month&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Used the Smoke Free app in the past 6 months
    </Exclusion_Criteria>
    <Condition>Smoking cessation &lt;br&gt;Not Applicable
    </Condition>
    <Intervention>&lt;br&gt;                This will be a two-arm individually randomized controlled effectiveness trial. Participants will be adult smokers who are intending to quit in the next 4 weeks, willing to participate in a 30-week study of their smoking and able to provide consent.&lt;br&gt;&lt;br&gt;                Those who are eligible and consent to participate in the trial will be randomized at that point to intervention or comparator conditions. Randomization will be 1:1 at the individual level with no restriction (i.e. no blocking) and will be automated using a random number function.&lt;br&gt;&lt;br&gt;                After consenting, participants in the comparator condition will receive a message encouraging them to make a quit attempt within the next 4 weeks and reminding them of the importance of responding to follow-up requests which are designed to track their progress.&lt;br&gt;&lt;br&gt;                Participants in the intervention condition will receive the same advice as those in the comparator condition plus offer of the full version of the Smoke Free app free of charge, encouragement to use the app and a link to download it. The Smoke Free app is based on behaviour change techniques that would be expected from theory and evidence with face-to-face support to aid smoking cessation. It guides smokers through the first month of their quit attempt by helping them to maintain their resolve by setting a clear goal, monitoring their progress towards that goal and becoming aware of benefits of being smoke-free achieved to date. The app has several components:&lt;br&gt;                1. A calculator which tracks the total amount of money not spent on buying cigarettes and the number of cigarettes not smoked (‘Dashboard')&lt;br&gt;                2. A calendar which tracks the amount of time elapsed since cessation (‘Dashboard')&lt;br&gt;            
    </Intervention>
    <Primary_outcome>Self-reported smoking cessation for at least 26 weeks, assessed 30 weeks after enrolment
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Assessed using self report:&lt;br&gt;                1. Having made at least one quit attempt in the 4 weeks following enrolment in the study&lt;br&gt;                2. Smoking cessation for at least 12 weeks, assessed 4 weeks after enrolment&lt;br&gt;                3. Downloading or using the Smoke Free app at least once, assessed 30 weeks after enrolment&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CEHP/2016/556
    </Secondary_ID>
    <Source_Support>Cancer Research UK
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 06/09/2019, UCL Research Ethics Committee (University College London, 2 Taviton St, London WC1E 6BT, UK. +44 (0)207 6798717; ethics@ucl.ac.uk), ref: CEHP/2016/556
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/12/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>11596381
    </Internal_Number>
    <TrialID>NCT04568499
    </TrialID>
    <Last_Refreshed_on>15 November 2021
    </Last_Refreshed_on>
    <Public_title>Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings
    </Public_title>
    <Scientific_title>Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings: a Prospective Cohort Study in South Sudan and DRC
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins Bloomberg School of Public Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200924
    </Date_registration3>
    <Date_registration>24/09/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04568499
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 27, 2020
    </Date_enrollement>
    <Target_size>592
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Congo, The Democratic Republic of the;South Sudan;Congo, The Democratic Republic of the;South Sudan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Shannon Doocy, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Johns Hopkins Bloomberg School of Public Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Suspected, probable, and confirmed COVID-19 cases presenting for care at participating&#x0D;&lt;br&gt;             health facilities (either by walk-in, referral or transfer) or identified by mobile&#x0D;&lt;br&gt;             contact tracing teams.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals unable or unwilling to give informed consent (e.g., due to mental&#x0D;&lt;br&gt;             impairment)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>COVID-19
    </Condition>
    <Primary_outcome>Hospitalization;Mortality
    </Primary_outcome>
    <Secondary_ID>13736
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>International Medical Corps;Centers for Disease Control and Prevention
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>9662840
    </Internal_Number>
    <TrialID>ISRCTN17717312
    </TrialID>
    <Last_Refreshed_on>17 August 2020
    </Last_Refreshed_on>
    <Public_title>CORONATION: Coronavirus (COVID-19) multinational observational registry
    </Public_title>
    <Scientific_title>Coronavirus (COVID-19) Multinational observational registry (CORONATION)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Cambridge University Hospitals NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200723
    </Date_registration3>
    <Date_registration>23/07/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN17717312
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>30/07/2020
    </Date_enrollement>
    <Target_size>10000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational epidemiological study (Screening)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Kerrie
    </Contact_Firstname>
    <Contact_Lastname>Brusby
    </Contact_Lastname>
    <Contact_Address>
                    Cambridge Clinical Trials Centre (CCTU)
                    Cambridge University Hospitals (CUH) NHS Foundation Trust
                    Addenbrooke’s Hospital
                    Cambridge Biomedical Campus
                    Box 4
    </Contact_Address>
    <Contact_Email>add-tr.coronation@nhs.net
    </Contact_Email>
    <Contact_Tel>+44 (0)1223254472
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                All COVID-19 cases are eligible for inclusion (COVID-19 cases that pre-decease the start of the registry are eligible)&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)
    </Condition>
    <Intervention>&lt;br&gt;                The CORONATION registry is a patient-level disease registry capturing identifiable patient data on UK COVID-19 cases and anonymised or identifiable data on international COVID-19 cases.&lt;br&gt;&lt;br&gt;                Care teams will collect demographic and clinical data on confirmed COVID-19 cases and enter this information into a database. This will be undertaken through a simple enrollment process and linkage with other datasets.&lt;br&gt;&lt;br&gt;                Baseline data collected will include baseline demographic data, baseline clinical data (comorbidities, medication, COVID-19 status and symptoms).&lt;br&gt;
    </Intervention>
    <Primary_outcome>Demographic and clinical data on confirmed COVID-19 cases (comorbidities, medication, COVID-19 status and symptoms) collected regularly from participating centres by entering data into an online portal
    </Primary_outcome>
    <Secondary_outcome>There are no secondary outcome measures
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CCTU0304, IRAS 282239
    </Secondary_ID>
    <Source_Support>Cambridge Biomedical Research Centre 
    </Source_Support>
    <Secondary_Sponsor>University of Cambridge
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 20/07/2020, University of Cambridge Human Biology Research Ethics Committee (17 Mill Lane, Cambridge, CB2 1RX; +44 (0)1223 766894; cb480@admin.cam.ac.uk), ref: HBREC.2020.32
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>24/04/2025
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>12057010
    </Internal_Number>
    <TrialID>ISRCTN80453162
    </TrialID>
    <Last_Refreshed_on>21 March 2022
    </Last_Refreshed_on>
    <Public_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study)
    </Public_title>
    <Scientific_title>The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery. An international cohort study (COVER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>University Hospitals Coventry and Warwickshire NHS Trust
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200414
    </Date_registration3>
    <Date_registration>14/04/2020
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN80453162
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/04/2020
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational longitudinal study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;England;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname>Ruth;Sandip
    </Contact_Firstname>
    <Contact_Lastname>Benson;Nandhra
    </Contact_Lastname>
    <Contact_Address>Vascular and Endovascular Research Network (President);Vascular and Endovascular Research Network
    </Contact_Address>
    <Contact_Email>vern.arterial.disease@gmail.com;vern.arterial.disease@gmail.com
    </Contact_Email>
    <Contact_Tel>+44 (0)121 4143344;+44 (0)191 2336161
    </Contact_Tel>
    <Contact_Affiliation>;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Any patient with a vascular condition
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Does not meet inclusion criteria
    </Exclusion_Criteria>
    <Condition>Any vascular condition, including: aortic or other type of aneurysmal disease, peripheral arterial disease, venous disease, vascular malformations, trauma, major haemorrhage, access (for renal dialysis), carotid (and cerebrovascular) disease, any other type of pathology treated by vascular surgeons. &lt;br&gt;Circulatory System
    </Condition>
    <Intervention>&lt;br&gt;                This project is a three-tiered study designed to fully elucidate the impact of the COVID-19 pandemic on vascular surgery across the world.&lt;br&gt;&lt;br&gt;                The aim of Tier 1 is to document how the provision and availability of vascular services evolves over time per unit/region/country.&lt;br&gt;&lt;br&gt;                The aim of Tier 2  is to prospectively capture data on all vascular procedures performed during the pandemic and understand the impact on outcomes in the short and medium-term (up to 1 year).&lt;br&gt;&lt;br&gt;                The aim of Tier 3 is to document (prospectively) deviations from standards of care/practice during the pandemic in vascular patients.&lt;br&gt;&lt;br&gt;                The main objective of the COVER study is to understand and evaluate the impact of the COVID-19 pandemic on global vascular practice and the effect on outcomes for patients presenting/receiving treatment during the pandemic.&lt;br&gt;                Population (patients) – All patients with a vascular pathology.&lt;br&gt;                Outcome of interest – Tier 1: state of vascular services per centre weekly; Tier 2: procedures performed in each centre; Tier 3: assessment of longer-term outcomes.&lt;br&gt;                Time – end of study 12 months after the end of the COVID19 pandemic.&lt;br&gt;&lt;br&gt;                The study is formally supported by the Vascular Society of Great Britain and Ireland (VSGBI),  the British Society for Endovascular Therapy (BSET), the Rouleaux Club, the NIHR, SingVasc and several national vascular surgery societies in Europe, Asia, Australia, New Zealand, and the Americas.&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Structure and processes within the vascular service measured using a novel online questionnaire weekly until the end of data collection&lt;br&gt;                2. Document all vascular surgery and interventional procedures performed using an online purpose-built data collection tool (per centre/patient) at baseline, time/date of surgery, date of discharge from hospital, three, six, and twelve months:&lt;br&gt;                2.1. Type of procedure performed&lt;br&gt;                2.2. Time taken from presentation to the surgical team to intervention&lt;br&gt;                2.3. Mode of referral (primary vs. secondary care)&lt;br&gt;                2.4. Site of surgery – hub or spoke hospital&lt;br&gt;                2.5. Imaging modalities used and timings&lt;br&gt;                2.6. Emergency classification i.e. urgent/emergency/elective&lt;br&gt;                2.7. Operative technique(s) and device(s) used&lt;br&gt;                2.8. Mode(s) of anaesthesia (local, regional, general, locoregional, other)&lt;br&gt;                2.9. Whether suspected or confirmed COVID-19 positive (+ve) at time of surgery, COVID-19 +ve after surgery, or COVID-19 negative (-ve)&lt;br&gt;                2.10. Documentation of changes to usual practice for this specific procedure as per surgeon’s standard protocol (type of procedure, type of anaesthetic, post-procedural destination)&lt;br&gt;                3. Management of all referred urgent vascular cases using the online survey, focusing on:&lt;br&gt;                3.1.  Chronic Limb Threatening Ischaemia (CLTI):&lt;br&gt;                3.1.1. Decision to discharge/admit/refer to a "hot"/emergency clinic&lt;br&gt;                3.1.2. Decision for endovascular or open surgery first&lt;br&gt;                3.1.3. Decision for best medical therapy or palliation or primary amputation&lt;br&gt;                3.2. Carotid disease:&lt;br&gt;                3.2.1. Number of patients managed with best medical therapy (BMT)&lt;br&gt;                3.2.2. Modifications to the indication and decision for carotid endarterectomy (CEA)&lt;br&gt;                3.2.3. Delays to treatment due to lack of theatre/bed availability&lt;br&gt;                3.3. Abdominal Aortic Aneurysm (AAA)&lt;br&gt;                3.3.1. Increasing use of Endovascular repair (if applicable)&lt;br&gt;                3.3.2. Changes to criteria for intervention&lt;br&gt;                3.3.3. Decisions for palliation, i.e. ‘turn down’&lt;br&gt;                3.4. Acute Aortic syndrome (AAS)&lt;br&gt;                3.4.1. Decision to manage in non-critical care beds&lt;br&gt;                3.4.2. Changes to imaging protocol at unit level&lt;br&gt;                3.4.3. Decision to defer surgery&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Collected after surgery has been performed at three, six, and twelve months using patient records:&lt;br&gt;                1.1. Re-admission&lt;br&gt;                1.2. Re-intervention&lt;br&gt;                1.3. All-cause mortality&lt;br&gt;                1.4. Operation-specific morbidity&lt;br&gt;                1.5. Morbidity&lt;br&gt;                1.6. [If COVID-19 +ve] - respiratory outcome, admission to intensive care unit&lt;br&gt;                2. Condition-specific outcomes at 3, 6 months and 1 year:&lt;br&gt;                2.1. CLTI - limb salvage, amputation free survival, all-cause mortality&lt;br&gt;                2.2. Carotid disease - ipsilateral stroke rate, any stroke rate, all-cause mortality&lt;br&gt;                2.3. AAA - aneurysm-related mortality, all-cause mortality&lt;br&gt;                2.4. AAS - complication rate including ruptures, all-cause mortality&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;COVER_01, IRAS 282224
    </Secondary_ID>
    <Source_Support>National Institute for Health Research
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Approved 02/04/2020, Liverpool Central NHS Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8056; liverpoolcentral.rec@hra.nhs.uk), ref: 20/NW/0196
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/04/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>8116835
    </Internal_Number>
    <TrialID>ISRCTN14071325
    </TrialID>
    <Last_Refreshed_on>17 June 2019
    </Last_Refreshed_on>
    <Public_title>An international study to investigate rates of death and illness following liver surgery
    </Public_title>
    <Scientific_title>International Snapshot Study on the Outcomes of Liver surgery - LiverGroup.org                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Royal Free London NHS Foundation Trust, UCL Partners
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190213
    </Date_registration3>
    <Date_registration>13/02/2019
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN14071325
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/2019
    </Date_enrollement>
    <Target_size>2000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational snapshot study  (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Aland Islands;Albania;Algeria;American Samoa;Andorra;Angola;Anguilla;Antarctica;Antigua and Barbuda;Argentina;Armenia;Aruba;Australia;Austria;Azerbaijan;Bahamas;Bahrain;Bangladesh;Barbados;Belarus;Belgium;Belize;Benin;Bermuda;Bhutan;Bolivia;Bonaire Saint Eustatius and Saba;Bosnia and Herzegovina;Botswana;Bouvet Island;Brazil;British Indian Ocean Territory;Brunei;Bulgaria;Burkina Faso;Burundi;Cambodia;Cameroon;Canada;Cape Verde;Cayman Islands;Central African Republic;Chad;Chile;China;Christmas Island;Cocos (Keeling) Islands;Colombia;Comoros;Congo;Congo, Democratic Republic;Cook Islands;Costa Rica;Cote d'Ivoire;Croatia;Cuba;Curacao;Cyprus;Czech Republic;Denmark;Djibouti;Dominica;Dominican Republic;Ecuador;Egypt;El Salvador;Equatorial Guinea;Eritrea;Estonia;Ethiopia;Falkland Islands;Faroe Islands;Fiji;Finland;France;French Guiana;French Polynesia;French Southern Territories;Gabon;Gambia;Georgia;Germany;Ghana;Gibraltar;Greece;Greenland;Grenada;Guadeloupe;Guam;Guatemala;Guernsey;Guinea;Guinea-Bissau;Guyana;Haiti;Heard Island and Mcdonald Islands;Holy See (Vatican City State);Honduras;Hong Kong;Hungary;Iceland;India;Indonesia;Iran;Iraq;Ireland;Isle of Man;Israel;Italy;Jamaica;Japan;Jersey;Jordan;Kazakhstan;Kenya;Kiribati;Korea, North;Korea, South;Kosovo;Kuwait;Kyrgyzstan;Laos;Latvia;Lebanon;Lesotho;Liberia;Libya;Liechtenstein;Lithuania;Luxembourg;Macao;Macedonia;Madagascar;Malawi;Malaysia;Maldives;Mali;Malta;Marshall Islands;Martinique;Mauritania;Mauritius;Mayotte;Mexico;Micronesia, Federated States of;Moldova;Monaco;Mongolia;Montenegro;Montserrat;Morocco;Mozambique;Myanmar;Namibia;Nauru;Nepal;Netherlands;Netherlands Antilles;New Caledonia;New Zealand;Nicaragua;Niger;Nigeria;Niue;Norfolk Island;Northern Mariana Islands;Norway;Oman;Pakistan;Palau;Palestinian Territory;Panama;Papua New Guinea;Paraguay;Peru;Philippines;Pitcairn;Poland;Portugal;Puerto Rico;Qatar;Reunion;Romania;Russian Federation;Rwanda;Saint Barthelemy;Saint Helena;Saint Kitts and Nevis;Saint Lucia;Saint Martin (French part);Saint Pierre and Miquelon;Saint Vincent and the Grenadines;Samoa;San Marino;Sao Tome and Principe;Saudi Arabia;Senegal;Serbia;Seychelles;Sierra Leone;Singapore;Sint Maarten (Dutch part);Slovakia;Slovenia;Solomon Islands;Somalia;South Africa;South Georgia and the South Sandwich Is;South Sudan;Spain;Sri Lanka;Sudan;Suriname;Svalbard and Jan Mayen;Swaziland;Sweden;Switzerland;Syria;Taiwan;Tajikistan;Tanzania;Thailand;Timor-Leste;Togo;Tokelau;Tonga;Trinidad and Tobago;Tunisia;Turkey;Turkmenistan;Turks and Caicos Islands;Tuvalu;Uganda;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;United States of America;Uruguay;Uzbekistan;Vanuatu;Venezuela;Viet Nam;Virgin Islands, British;Virgin Islands, U.S.;Wallis and Futuna;Western Sahara;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. All liver surgery indications (including benign and living donor resections, open, laparoscopic or robotic surgery, single wedge resections to extended liver resections, single- or two-stage hepatectomies, procedures with liver volume enhancement such as PVE, PVL, ALPPS, resections involving cold perfusion (ex-situ and ante-situ)&lt;br&gt;                2. Any co-morbidity&lt;br&gt;&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Liver transplantation&lt;br&gt;                2. Imaging-guided RFA, MWA, or other ablation techniques&lt;br&gt;                3. Liver biopsies&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Any indication for liver surgery &lt;br&gt;Surgery
    </Condition>
    <Intervention>The intervention includes any type of liver surgery. The patients's progress will be observed from the day of the operation until hospital discharge as well as up to 90 days postoperatively.
    </Intervention>
    <Primary_outcome>Death recorded up to 90 days postoperatively using the patients' medical records
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Postoperative complications as measured by the Clavien-Dindo Classification, FABIB Liver-Specific Classification and the Comprehensive Complication Index® (CCI®)&lt;br&gt;                2. Liver failure as measured by the FABIB Liver-Specific Classification, the ISGLS criteria and the 50-50 criteria up to 90 days postoperatively&lt;br&gt;                3. Length of hospital stay (defined as the duration of hospitalization from the day of the operation until the day of discharge from the hospital) recorded up to 90 days postoperatively using the patients' medical records&lt;br&gt;                4. Rehospitalization (defined as any readmission to any hospital within 90 days from the operation) assessed using the patients' medical records up to 90 days postoperatively using the patients' medical records&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NCT03768141;v.1.3
    </Secondary_ID>
    <Source_Support>Royal Free Hospital, Universidad de Zaragoza
    </Source_Support>
    <Secondary_Sponsor>Department of Surgery, University Hospital Miguel Servet, University of Zaragoza, Spain
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This project is considered as an audit and does not require ethics committee approval in the UK. 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>10/03/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>8681476
    </Internal_Number>
    <TrialID>ISRCTN89017827
    </TrialID>
    <Last_Refreshed_on>6 January 2020
    </Last_Refreshed_on>
    <Public_title>Wasting and stunting in young children in developing countries
    </Public_title>
    <Scientific_title>Children who are both wasted and stunted are also underweight and have a high risk of death – policy implications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Emergency Nutrition Network
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170821
    </Date_registration3>
    <Date_registration>21/08/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN89017827
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>01/01/1992
    </Date_enrollement>
    <Target_size>1796991
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Observational cross-sectional study (Other)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Afghanistan;Albania;Algeria;American Samoa;Angola;Bahrain;Bangladesh;Benin;Burkina Faso;Burundi;Cambodia;Cameroon;Cape Verde;Central African Republic;Chad;Congo;Congo, Democratic Republic;Cote d'Ivoire;Djibouti;Ecuador;Equatorial Guinea;Eritrea;Ethiopia;Gabon;Gambia;Ghana;Guinea-Bissau;Haiti;India;Indonesia;Kenya;Laos;Lesotho;Liberia;Madagascar;Malawi;Mali;Mauritania;Mozambique;Myanmar;Namibia;Nepal;Niger;Nigeria;Pakistan;Rwanda;Senegal;Sierra Leone;Somalia;South Sudan;Sudan;Tajikistan;Tanzania;Timor-Leste;Uganda;Yemen;Zambia;Zimbabwe
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. 6-59 month old children&lt;br&gt;                2. Males and females&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children over 59 months of age
    </Exclusion_Criteria>
    <Condition>Nutrition &lt;br&gt;Nutritional, Metabolic, Endocrine
    </Condition>
    <Intervention>A database of cross-sectional survey datasets containing data for almost 1.8 million children was compiled. This was analysed to determine the intersection between sets of wasted, stunted, and underweight children; the association between being wasted and being stunted; the severity of wasting and stunting in WaSt children; and the prevalence of WaSt by age and sex. An additional analysis of the WHO Growth Standards sought the maximum possible weight-for-age z-score for WaSt children.
    </Intervention>
    <Primary_outcome>Overlap between wasted, stunted and underweight children as measured by &lt;-2SD WHZ, HAZ, WAZ
    </Primary_outcome>
    <Secondary_outcome>Degree of concurrence i.e. &lt;-2SDWHZ AND ,-2SDHAZ in children and by age (6-59 months) and by sex (male/female) 
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>United States Agency for International Development, 295 Grant Number: ENN AID-OFDA-G-15-00190 , Irish Aid
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1990
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>This is an observational study so does not need ethical approval. All data was anonymous and was secondary and readily available for further analysis. There were no human or animal subjects.
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/12/2015
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>11/03/2022 15:30:05</Export_date>
    <Internal_Number>9582192
    </Internal_Number>
    <TrialID>ISRCTN30393230
    </TrialID>
    <Last_Refreshed_on>20 July 2020
    </Last_Refreshed_on>
    <Public_title>Combined protocol for acute malnutrition study (ComPAS)
    </Public_title>
    <Scientific_title>Combined Protocol for Acute Malnutrition Study (ComPAS) - effectiveness of a combined and simplified protocol for the treatment of acute malnutrition: a prospective, multi-center cluster-randomized controlled non-inferiority trial in Kenya and South Sudan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>London School of Hygiene &amp; Tropical Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170316
    </Date_registration3>
    <Date_registration>16/03/2017
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>http://isrctn.com/ISRCTN30393230
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>08/05/2017
    </Date_enrollement>
    <Target_size>2400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cluster-randomized controlled non-inferiority trial (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Kenya;South Sudan
    </Countries>
    <Contact_Firstname>Jeanette
    </Contact_Firstname>
    <Contact_Lastname>Bailey
    </Contact_Lastname>
    <Contact_Address>
                    International Rescue Committee
                    122 E 42nd Street
                
    </Contact_Address>
    <Contact_Email>jeanette.bailey@rescue.org
    </Contact_Email>
    <Contact_Tel>+1 (0)212 551 2951
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                Current participant inclusion criteria as of 01/04/2019:&lt;br&gt;                1. Children aged 6 to 59 months&lt;br&gt;                2. Diagnosed with uncomplicated acute malnutrition and eligible for CMAM treatment, defined as &lt;125mm MUAC and/or bilateral pitting oedema (+/++) in the intervention arm or &lt;125mm MUAC and/or bilateral pitting oedema (+/++) and/or WHZ &lt;-2 in the control arm&lt;br&gt;                3. Passes appetite test (consumption of 30g of RUTF within 20 minutes)&lt;br&gt;                4. No medical complications&lt;br&gt;&lt;br&gt;                Previous participant inclusion criteria:&lt;br&gt;                1. Children aged 6 to 59 months&lt;br&gt;                2. Diagnosed with uncomplicated acute malnutrition and eligible for CMAM treatment, defined as &lt;125mm MUAC and/or bilateral pitting oedema (+) in the intervention arm or &lt;125mm MUAC and/or bilateral pitting oedema (++/+++) and/or WHZ &lt;-2 in the control arm&lt;br&gt;                3. Passes appetite test (consumption of 30g of RUTF within 20 minutes)&lt;br&gt;                4. No medical complications&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                Current participant exclusion criteria as of 01/04/2019:&lt;br&gt;                1. =125 mm MUAC&lt;br&gt;                2. Failed appetite test (requires inpatient treatment)&lt;br&gt;                3. Medical complications requiring inpatient treatment, as per international guidelines/ IMCI danger signs including but not limited to:&lt;br&gt;                3.1. Oedema (+++ or higher)&lt;br&gt;                3.2. Anorexia, no appetite&lt;br&gt;                3.3. Intractable vomiting&lt;br&gt;                3.4. Convulsions&lt;br&gt;                3.5. Lethargy, not alert&lt;br&gt;                3.6. Unconsciousness&lt;br&gt;                3.7. Hypoglycaemia&lt;br&gt;                3.8. High fever&lt;br&gt;                3.9. Hypothermia&lt;br&gt;                3.10. Severe dehydration&lt;br&gt;                3.11. Lower respiratory tract infection&lt;br&gt;                3.12. Severe anaemia&lt;br&gt;                3.13. Skin lesions&lt;br&gt;&lt;br&gt;                Previous participant exclusion criteria:&lt;br&gt;                1. =125mm MUAC&lt;br&gt;                2. Failed appetite test (requires inpatient treatment)&lt;br&gt;                3. Medical complications requiring inpatient treatment, as per international guidelines/ IMCI danger signs including but not limited to:&lt;br&gt;                3.1. Oedema (++ or higher)&lt;br&gt;                3.2. Anorexia, no appetite&lt;br&gt;                3.3. Intractable vomiting&lt;br&gt;                3.4. Convulsions&lt;br&gt;                3.5. Lethargy, not alert&lt;br&gt;                3.6. Unconsciousness&lt;br&gt;                3.7. Hypoglycaemia&lt;br&gt;                3.8. High fever&lt;br&gt;                3.9. Hypothermia&lt;br&gt;                3.10. Severe dehydration&lt;br&gt;                3.11. Lower respiratory tract infection&lt;br&gt;                3.12. Severe anaemia&lt;br&gt;                3.13. Skin lesions&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Non-complicated acute malnutrition among children 6-59 months &lt;br&gt;Nutritional, Metabolic, Endocrine &lt;br&gt;Malnutrition
    </Condition>
    <Intervention>&lt;br&gt;                Current interventions as of 01/04/2019:&lt;br&gt;                The intervention tested involves the nutritional treatment of malnourished children age 6-59 months with ready-to use therapeutic foods in Kenya and South Sudan. The unit of randomization will be health facilities stratified by country and then randomly assigned to the control or intervention group. The control arm of the study will adhere to national protocols for the admission, case management and treatment of severe acute malnutrition using RUTF known as plumpy'nut or moderate acute malnutrition using RUSF known as plumpy'sup within the traditional OTP and SFP structures. The intervention arm will follow a combined, simplified protocol for the admission of acutely malnourished children based on mid upper arm circumference (MUAC), case management and treatment based on a reduced dosage of RUTF plumpy'nut. This will continue until discharge. The basic medical treatment of the children admitted with MUAC &lt;115mm and/or bipedal oedema (+/++) on admission and/or weight for height z-score &lt;-3 will be the same between the 2 groups and will follow the recommendations for the management of severe acute malnutrition as per the national protocols in Kenya and South Sudan. The nutritional treatment dosage scheme for the 2 groups is described below.&lt;br&gt;&lt;br&gt;                Control arm:&lt;br&gt;                OTP admission - plumpy'nut RUTF 200kcal/kg/day; received weekly&lt;br&gt;                SFP admission - plumpy'sup RUSF 500 kcal/day; received bi-weekly&lt;br&gt;&lt;br&gt;                Intervention arm:&lt;br&gt;                &lt;115mm and/or oedema (+/++) - two 92g sachets RUTF/day (1000 kcal/day); received weekly&lt;br&gt;                115-&lt;125mm – one 92g sachet RUTF/day (500 kcal/day); received bi-weekly&lt;br&gt;&lt;br&gt;&lt;br&gt;                Previous interventions:&lt;br&gt;   
    </Intervention>
    <Primary_outcome>Recovery from acute malnutrition, defined as two consecutive measurements with a MUAC =125mm and no oedema, is assessed by reviewing patient records at end of treatment. 
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Current secondary outcome measures as of 02/04/2019:&lt;br&gt;                1. Coverage, defined as % of children eligible for treatment (MUAC&lt;125mm) who receive it, is measured using a SQUEAC survey at the end of the research enrolment period&lt;br&gt;                2. Program default, defined by 3 consecutive missed visits in South Sudan or 3 consecutive missed visits in Kenya, is measured by reviewing patient records monthly for the duration of the&lt;br&gt;                3. Program death rate is measured by reviewing patient records monthly for the duration of the&lt;br&gt;                4. Length of stay in treatment is measured by reviewing patient records to determine the duration of treatment (days) until recover), at end of treatment&lt;br&gt;                5. Average daily weight gain (g/kg/day) is measured by reviewing patient records at end of treatment&lt;br&gt;                6. Average daily MUAC gain (mm/day) is measured by reviewing patient records at end of treatment&lt;br&gt;&lt;br&gt;                Previous secondary outcome measures:&lt;br&gt;                1. Coverage, defined as % of children eligible for treatment (MUAC&lt;125mm) who receive it, is measured using a SQUEAC survey at the end of the research enrolment period&lt;br&gt;                2. Program default, defined by 2 consecutive missed visits in South Sudan or 3 consecutive missed visits in Kenya, is measured by reviewing patient records monthly for the duration of the&lt;br&gt;                3. Program death rate is measured by reviewing patient records monthly for the duration of the&lt;br&gt;                4. Length of stay in treatment is measured by reviewing patient records to determine the duration of treatment (days) until recover), at end of treatment&lt;br&gt;                5. Average daily weight gain (g/kg/day) is measured by reviewing patient records at end of treatment&lt;br&gt;                6. Average daily MUAC gain (mm/day) is measured by reviewing patient records at end of treatment&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>N/A
    </Secondary_ID>
    <Source_Support>Children's Investment Fund Foundation, United States Agency for International Development/Office of Disaster Assistance
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>
                    1. London School of Hygiene and Tropical Medicine, 28/11/2016, ref: 11826
                    2. Kenya Medical Research Institute, 5/1/2017, ref: 551
                    3. Internal Review Board Ministry of Health Government of South Sudan, 21/11/2016
                
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/08/2018
    </results_date_completed>
    <results_url_link/>
    
  </Trial>
</Trials_downloaded_from_ICTRP>